187 related articles for article (PubMed ID: 37310446)
61. Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT
Sniecikowska J; Gluch-Lutwin M; Bucki A; Więckowska A; Siwek A; Jastrzebska-Wiesek M; Partyka A; Wilczyńska D; Pytka K; Pociecha K; Cios A; Wyska E; Wesołowska A; Pawłowski M; Varney MA; Newman-Tancredi A; Kolaczkowski M
J Med Chem; 2019 Mar; 62(5):2750-2771. PubMed ID: 30721053
[TBL] [Abstract][Full Text] [Related]
62. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
van Amsterdam C; Seyfried CA
Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
[TBL] [Abstract][Full Text] [Related]
63. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism.
du Jardin KG; Jensen JB; Sanchez C; Pehrson AL
Eur Neuropsychopharmacol; 2014 Jan; 24(1):160-71. PubMed ID: 23916504
[TBL] [Abstract][Full Text] [Related]
64. The selective 5-HT
Depoortere R; Johnston TH; Fox SH; Brotchie JM; Newman-Tancredi A
Parkinsonism Relat Disord; 2020 Sep; 78():151-157. PubMed ID: 32846366
[TBL] [Abstract][Full Text] [Related]
65. The Antidepressant-Like Effects of a Clinically Relevant Dose of Ketamine Are Accompanied by Biphasic Alterations in Working Memory in the Wistar Kyoto Rat Model of Depression.
McDonnell CW; Dunphy-Doherty F; Rouine J; Bianchi M; Upton N; Sokolowska E; Prenderville JA
Front Psychiatry; 2020; 11():599588. PubMed ID: 33551869
[TBL] [Abstract][Full Text] [Related]
66. The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.
Kaminska K; Rogoz Z
J Physiol Pharmacol; 2016 Jun; 67(3):471-80. PubMed ID: 27512008
[TBL] [Abstract][Full Text] [Related]
67. Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects.
Zhang GF; Liu WX; Qiu LL; Guo J; Wang XM; Sun HL; Yang JJ; Zhou ZQ
Eur Psychiatry; 2015 Jun; 30(4):504-10. PubMed ID: 25795441
[TBL] [Abstract][Full Text] [Related]
68. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.
Dawson LA; Watson JM
CNS Neurosci Ther; 2009; 15(2):107-17. PubMed ID: 19499624
[TBL] [Abstract][Full Text] [Related]
69. Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats.
Tizabi Y; Bhatti BH; Manaye KF; Das JR; Akinfiresoye L
Neuroscience; 2012 Jun; 213():72-80. PubMed ID: 22521815
[TBL] [Abstract][Full Text] [Related]
70. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
71. Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents.
Rosenzweig-Lipson S; Sabb A; Stack G; Mitchell P; Lucki I; Malberg JE; Grauer S; Brennan J; Cryan JF; Sukoff Rizzo SJ; Dunlop J; Barrett JE; Marquis KL
Psychopharmacology (Berl); 2007 Jun; 192(2):159-70. PubMed ID: 17297636
[TBL] [Abstract][Full Text] [Related]
72. HBK-14 and HBK-15 with antidepressant-like and/or memory-enhancing properties increase serotonin levels in the hippocampus after chronic treatment in mice.
Pytka K; Gawlik K; Pawlica-Gosiewska D; Witalis J; Waszkielewicz A
Metab Brain Dis; 2017 Apr; 32(2):547-556. PubMed ID: 27888375
[TBL] [Abstract][Full Text] [Related]
73. AMPA receptors mediate the pro-cognitive effects of electrical and optogenetic stimulation of the medial prefrontal cortex in antidepressant non-responsive Wistar-Kyoto rats.
Papp M; Gruca P; Lason M; Litwa E; Solecki W; Willner P
J Psychopharmacol; 2020 Dec; 34(12):1418-1430. PubMed ID: 33200659
[TBL] [Abstract][Full Text] [Related]
74. Stress and Ketamine, Bimodal Influence on Cognitive Functions.
Trofimiuk E; Wielgat P; Braszko JJ; Car H
Behav Brain Res; 2019 Mar; 360():354-364. PubMed ID: 30562568
[TBL] [Abstract][Full Text] [Related]
75. Role of 5-HT
Vilela-Costa HH; Maraschin JC; Casarotto PC; Sant'Ana AB; de Bortoli VC; Vicente MA; Campos AC; Guimarães FS; Zangrossi H
Behav Brain Res; 2021 Apr; 404():113159. PubMed ID: 33571572
[TBL] [Abstract][Full Text] [Related]
76. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
77. Perinatal exposure to 5-methoxytryptamine, behavioural-stress reactivity and functional response of 5-HT1A receptors in the adolescent rat.
Cannizzaro C; Plescia F; Gagliano M; Cannizzaro G; Mantia G; La Barbera M; Provenzano G; Cannizzaro E
Behav Brain Res; 2008 Jan; 186(1):98-106. PubMed ID: 17825441
[TBL] [Abstract][Full Text] [Related]
78. 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential.
Koek W; Vacher B; Cosi C; Assié MB; Patoiseau JF; Pauwels PJ; Colpaert FC
Eur J Pharmacol; 2001 May; 420(2-3):103-12. PubMed ID: 11408031
[TBL] [Abstract][Full Text] [Related]
79. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.
Koek W; Patoiseau JF; Assié MB; Cosi C; Kleven MS; Dupont-Passelaigue E; Carilla-Durand E; Palmier C; Valentin JP; John G; Pauwels PJ; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1998 Oct; 287(1):266-83. PubMed ID: 9765347
[TBL] [Abstract][Full Text] [Related]
80. Bell-shaped agonist activation of 5-HT
Newman-Tancredi A; Cussac D; Ormière AM; Lestienne F; Varney MA; Martel JC
Cell Signal; 2019 Nov; 63():109383. PubMed ID: 31376526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
